References
- Whitmore A, Krishnaswami CS. An account of the discovery of a hitherto undiscovered infective disease occurring among the population of Rangoon. Indian Med. Gaz.47(7), 262–267 (1912).
- Chaowagul W, White NJ, Dance DAB et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J. Infect. Dis.159(5), 890–899 (1989).
- Puthucheary SD, Parasakthi N, Lee MK. Septicaemicmelioidosis – a review of 50 cases from Malaysia. Trans. Roy. Soc. Trop. Med. Hyg.86(6), 683–685 (1992).
- White NJ, Dance DAB, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet2(8665), 697–701 (1989).
- Simpson AJH, Suputtamongkol Y, Smith MD et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis.29(2), 381–387 (1999).
- Wong KT, Puthucheary SD, Vadivelu J. The histopathology of human melioidosis. Histopathology26(1), 51–55 (1995).
- Kespichayawattana W, Rattanachetkul S, Wanun T, Wanun T, Utaisincharoen P, Sirisinha S. Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading. Infect. Immun.68(9), 5377–5384 (2000).
- Vorachit M, Lam K, Jayanetra P, Costerton JW. Electron microscopic study of the mode of growth of Pseudomonas pseudomallei in vitro and in vivo. J. Trop. Med. Hyg.98(6), 379–3791 (1995).
- Puthucheary SD. Melioidosis in Malaysia. Med. J. Malaysia64(4), 266–274 (2010).
- Puthucheary SD, Nathan SA. Comparison by electron microscopy of intracellular events and survival of Burkholderia pseudomallei in monocytes from normal subjects and patients with melioidosis. Singapore Med. J.47(8), 697–703 (2006).
- Nathan SA, Quist R, Puthucheary SD. Kinetic studies of bioactive products nitric oxide and 8-iso-PGF2α in Burkholderia pseudomallei infected human macrophages, and their role in the intracellular survival of these organisms. FEMS Immunol. Med. Microbiol.43(2), 177–183 (2004).
- Sam IC, See KH, Puthucheary SD. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J. Clin. Microbiol.47(5), 1556–1558 (2009).
- White NJ. Melioidosis. Lancet361(9370), 1715–1722 (2003).
- Chantratita N, Rholl DA, Sim B et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc. Natl Acad. Sci. USA108(41), 17165–17170 (2011).
- Cheng CH, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ. Outcomes of patients with melioidosis treated with meropenem. Antimicrob. Agents Chemother.48(5), 1763–1765 (2004).
- Propst KL, Troyer RM, Kellihan LM, Schweizer HP, Dow SW. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob. Agents Chemother54(5), 1785–1792 (2010).